The U.S. Food and Drug Administration (FDA) has required product labeling updates for GLP-1 receptor agonist weight-loss and diabetes medications, including Wegovy Ozempic and Mounjaro, to include warnings about a rare optic nerve condition that can cause vision impairment. Experts advise patients taking these medications to seek immediate ophthalmologic care if they experience sudden blurred vision and to consult their prescribing physician regarding whether to continue treatment.
On the 9th, the FDA instructed pharmaceutical companies to add the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION) to the ‘Warnings and Precautions’ section of prescription product labeling for all GLP-1 receptor agonist treatments. Affected drugs include semaglutide (the active ingredient in Wegovy and Ozempic), tirzepatide (found in Mounjaro and Zepbound), and liraglutide (found in Saxenda).
This condition occurs when blood flow is blocked to the optic nerve. Representative symptoms include a painless, sudden decrease in vision in one eye or the partial loss of the field of vision, which can lead to permanent vision damage in severe cases. The FDA recommends that patients experiencing these symptoms immediately notify healthcare providers and promptly receive an eye examination.
